Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03836469

Acronym

RELANCE

Enrollment

403

Registered

2019-02-11

Start date

2019-09-25

Completion date

2022-06-09

Last updated

2024-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer, Non-small Cell

Keywords

Lung cancer, Non-small cell

Brief summary

RELANCE is a large multi-institutional study that aims to retrospectively collect information about diagnostic, treatment and outcome of patients diagnosed with locally advanced NSCLC in Brazil. It is hypothesized that there is a great heterogeneity in treatment patterns owing to inequities in access to adequate staging methods, optimal treatment and multidisciplinary teams in Brazil.

Detailed description

RELANCE study will collect sociodemographic and clinical data of patients diagnosed with locally advanced NSCLC in the period of January 2015 and Jun 2019 in the participating institutions. Socio-demographic characteristics, clinicopathological features, treatments patterns and outcomes will be recovered from medical charts. Disease status and survival data will be collected up to the last date of follow-up June 2021.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients aged 18 years or older; 2. Histologically or cytological diagnosis of NSCLC in the period of January 2015 to December 2016; 3. Locally Advanced NSCLC defined as clinical stage IIIA and IIIB according to 7th Edition TNM Staging System; 4. Any NSCLC histological subtype and molecular mutation; 5. Any Eastern Cooperative Oncology Group (ECOG) Performance Status (0 to 4) at diagnosis; 6. Patients assigned by treating physician to any therapy or palliative care; 7. Access to patient medical chart for data collection.

Exclusion criteria

1. Small cell lung cancer and non-invasive NSCLC; 2. Synchronic NSCLC or second primary tumour in the last 5 years (except non-melanoma skin cancer).

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	Up to June 30, 2018	defined as time from diagnosis to death of any cause;

Secondary

Measure	Time frame	Description
Progression free survival	Up to June 30, 2018	defined as time from any line of treatment to progression of the disease or death of any cause
Time to next treatment	Up to June 30, 2018	defined as time from start of the any treatment to the beginning of a second therapy

Countries

Brazil

Outcome results